NCT01097083终止2 期
A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 6
研究概览
简要总结
The hypothesis of this study is that the median time to progression in the experimental arm is 2 months as compared to the placebo arm of 1.4 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The diagnosis of HCC is made either by histological examination of tumor tissue or imaging evidence of a typical space-occupying lesion in the liver together with a serum AFP concentration of above 500 ng/ml (normal value, 10 ng/ml) in a known carrier of hepatitis B or C, or AFP above 400 ng/ml in non Hepatitis B or C carrier.
- •Patients with unresectable HCC that is not amenable to liver transplantation nor local ablative technique and who are not suitable for any conventional systemic therapy (including sorafenib and chemotherapy).
- •Patients with Child-Pugh Class C liver cirrhosis (Child-Pugh Scores of 10-15 points). Patients with Child-Pugh Class A or B liver cirrhosis who are not eligible for conventional therapy or other clinical trials or who refuse conventional therapy are included
- •Life Expectancy of at least 12 weeks
- •All patients should have anti-HBc antibodies tested if HBs Ag is negative. If anti-HBc is positive, HBV DNA detection should be performed to determine viral load. An undetectable Hep B DNA level (DNA levels < 12 IU/ml) in the presence of a positive Hep B core total antibody would indicate no active hepatitis infection and the subject would still be eligible for this trial.
- •Age >21 years.
- •Performance status ECOG 0 - 2
- •Patients must have normal organ and marrow function as defined below:
- •Absolute neutrophil count > 1.5 x 109/L Platelets > 50 x 109/L Haemoglobin > 9.0g/dl Total bilirubin < 51umol/L (3 mg /dL) AST (SGOT)/ALT (SGPT) < 5 X institutional ULN Creatinine < 1.5 ULN INR <1.7 or prothrombin time (PT) <4 seconds above ULN
- •Patients who have not received any local or systemic treatment in the last 4 weeks.
- •Measurable disease according to RECIST
- •Ability to understand and the willingness to sign a written informed consent document.
- •Ability to swallow oral medication
- •The effects of C versicolor on the developing human fetus are unknown. For this reason, woman of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
排除标准
- •Patients with a history of prior malignancy that is distinct in site and histology from HCC except non-melanoma skin cancer. Any cancer curatively treated more than 3 years prior to entry is permitted.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, intractable ascites that could not be controlled by medical therapy
- •Prior use of C versicolor or Yunzhi for HCC
- •Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- •Patients who are using other chinese herbal therapies concurrently or on any other investigation agents for treatment of their cancer
- •Known of history of allergic reactions attributed to compounds of similar chemical or biologic composition used in the study.
- •Presence of active hepatitis B/C flare.
- •Known history of Human Immunodeficiency Virus (HIV) Infection
- •Gastrointestinal disease which could affect the absorption or pharmacokinetics of the study drug as determined by investigator
- •Psychiatric illness/social situations that would limit compliance with study requirements. Patients with severe depression or psychiatric disorders will be excluded.
- •Known alcohol and/or substance abuser that may interfere with the subject's participation in the study or evaluation of study results.
- •Pregnancy or breast-feeding subjects. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the 14 days prior to study enrollment and must be willing to use adequate contraception
- •Patients suffering from autoimmune disease, patients on concomitant long-term immunosuppressant therapy and those scheduled to receive bone marrow transplants
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative CancerCancerNCT00420563Centre Oscar Lambret88
已完成
2 期
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate CancerProstatic NeoplasmsNCT00706628Boehringer Ingelheim87
进行中（未招募）
2 期
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCTMyeloid MalignanciesLymphoid MalignanciesNCT02452697Cristina Gasparetto36
已完成
2 期
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaHead and Neck NeoplasmsNeoplasm Recurrence, LocalNeoplasm MetastasisNCT00401323Sanofi568
已完成
2 期
A phase II study of withdrawal of imatinib therapy in adult patients with chronic phase chronic myeloid leukaemia in stable molecular remissioChronic phase chronic myeloid leukaemia in stable molecular remissionCancer - Leukaemia - Chronic leukaemiaACTRN12606000118505Australasian Leukaemia and Lymphoma Group40